ArticlePeerJ2020
Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer.
Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Effects and potential mechanisms of luteolin on cisplatin mediated inhibition of cervical adenocarcinoma.Open life sciences · 2026Article
- MiR-668-3p in M2 macrophage-derived exosomes activates autophagy through the ETS1/EGFR axis and promotes cisplatin resistance in gastric cancer.Cancer cell international · 2025Article
- Long noncoding RNAs involved in therapeutic response: implications for cervical cancer drug resistance.Frontiers in oncology · 2025Review
- Promising predictive molecular biomarkers for cervical cancer (Review).International journal of molecular medicine · 2024Review
- Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.Medical oncology (Northwood, London, England) · 2023Review
- Circular RNA ARHGAP5 inhibits cisplatin resistance in cervical squamous cell carcinoma by interacting with AUF1.Cancer science · 2023Article
- Cervical cancer heterogeneity: a constant battle against viruses and drugs.Biomarker research · 2022Review
- Knockdown of circ_0055412 promotes cisplatin sensitivity of glioma cells through modulation of CAPG and Wnt/β-catenin signaling pathway.CNS neuroscience & therapeutics · 2022Article
- Down-regulation of lncRNA LUADT1 suppresses cervical cancer cell growth by sequestering microRNA-1207-5p.Acta biochimica et biophysica Sinica · 2022Article
- Article
- The role of long noncoding RNAs in therapeutic resistance in cervical cancer.Frontiers in cell and developmental biology · 2022Review
- Mechanism of hydrogen on cervical cancer suppression revealed by high‑throughput RNA sequencing.Oncology reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) remains a major disease burden on the female population worldwide. Chemotherapy with cisplatin (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.